Indications of Herceptin® in breast cancer treatment;Indications de l'Herceptin® dans le traitement du cancer du sein

Gynecologie Obstetrique et Fertilite

Volumn 32, Issue 2, 2004, Pages 164-172

  Beuzeboc, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Cancer du sein m tastatique; Cardiotoxicit ; Cardiotoxicity; HER2; Metastatic breast cancer; Trastuzumab

Indexed keywords

PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; DRUG INDICATION; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT MONITORING; BREAST TUMOR; MORTALITY; PATHOLOGY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1442326148     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2003.12.006     Document Type: Article

References (59)

1. ®): une avancée thérapeutique majeure dans les cancers du sein exprimant cet oncogène. Bull Cancer. 86:(6):1999;544-548.
2. ®. Bull Cancer. 87:(11):2000;847-858.
3. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 3:2002;137-144.
4. Schechter A.C., Stern B.F., Vaidyanathan L., et al. The neu oncogene: an erbB-related gene encoding a 185 000-Mr tumor antigen. Nature. 312:1984;513-516.
5. Hung M.C., Lau Y.K. Basic science of HER2/neu: a review. Seminars Oncology. 26:(4 suppl 12):1999;51-59.
6. Slamon D.J., Clark G.M., Wrong S.G., et al. Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
7. Mitchell M.S., Press M.F. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognostic of breast cancer. Sem Oncol. 26:(suppl 12):1999;108-116.
8. Revillion F., Bonneterre J., Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer. 34:(6):1998;791-808.
9. Ross J.S., Fletcher J.A. The HER2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. The Oncologist. 3:1998;237-252.
10. Trock B.J., Yamauchi H., Brotzman M., et al. C-erbB2 as a prognostic factor in breast cancer: a meta-analysis. Proc ASCO. 19:2000;. abstract 372.
11. Press M.F., Berstein L., Thomas, et al. HER/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinoma. J Clin Oncol. 15:1997;2894-2904.
12. Kallioniemi O.P., Holli K., Visakorpi T., et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 49:(5):1991;650-655.
13. De Placido S., De Laurentiis M., Carlomagno C., et al. Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast. Cancer. Clin Cancer Res. 9:(3):2003 Mar;1039-1046.
14. Carlomagno C., Perrone F., Gallo C., et al. C-erbB2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary-lymph node metastases. J Clin Oncol. 14:1996;2702-2708.
15. Elledge R., Green S., Ciocca, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a southwest oncology study group. Clin Cancer Res. 4:(7):1998;12.
16. Houston S.J., Love S.B., Wright C., et al. C-erbB2 protein over-expression in breast cancer is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 79:1999;1220-1226.
17. Mitchell M.S., Press M.F. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognostic of breast cancer. Sem Oncol. 26:(suppl 12):1999;108-116.
18. Stal O., Sullivan S., Wingren S., et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur. J. Cancer. 31 A:(13/14):1995;2185-2190.
19. Muss H.B., Thor A.D., Berry D.A., et al. C-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 330:1994;1260-1266.
20. Paik S., Bryant J., Park C., et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 90:1998;1361-1370.
21. Thor A.D., Berry D.A., Budman D.R., et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 90:1998;1346-1360.
22. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1-1 and/or ErbB2-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 19:2001;3808-3816.
23. Nieto Y., Cagnoni P.J., Nawaz S., et al. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 18:2000;2070-2080.
24. Vincent-Salomon A., Carton M., Freneaux P. ERBB2 expression in breast carcinomas: no correlation with pathological response to high dose anthracycline-based chemotherapy. Eur J Cancer. 36:2000;586-591.
25. Baselga J., Seidman A.D., Rosen P.P., Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer, therapeutic implications. Oncology. 11:(3 Suppl 2):1997;43-48.
26. Pegram M.D., Finn R.S., Arzoo K., et al. The effect of c-erbB2 Her-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15:1997;537-547.
27. Pegram M.D., Slamon D.J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol. 26:(4 Suppl 12):1999;89-95.
28. ® monotherapy in women with HER-2positive meatstatic breast cancer: preliminary data from a phase II study. Proc ASCO. 2002;. Abstr 73.
29. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 14:1996;737-744.
30. Pegram M.D., Liphon A., Hayes D.F., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 16:(8):1998;2659-2671.
31. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17:1999;2639-2648.
32. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:(11):2001;783-792.
33. ®) as single agent in first-line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol. 20:(3):2002;719-726.
34. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 20:2002;1215-1221.
35. Zhao Y.-Y., Sawyer D.R., Ragavendra R., et al. Neuroregulins promote survival and growth of cardiac myocytes. J Biol Chem. 213:1998;10261-10269.
36. Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;334-335.
37. Crone A.S., Zhao Y.Y., Fan I., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8:2002;459-465.
38. Couturier J., Nicolas A., Beuzeboc P., et al. High correlation between ERBB2 amplification detected by FISH and gene overexpression detected by immuno-chemistry in breast cancers. Modern Pathology. 12:1999;18A.
39. Mass R.D., Sanders C., Charlene K., et al. The concordance between the clinical trials assay and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials. Proc ASCO. 2000;. Abstr 291.
40. Press M.F., Slamon D.J., Flam K.J., et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 20:2002;3095-3105.
41. Vincent-Salomon A., Jouve M., Genin M., et al. HER2 status in patients with breast carcinomas is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer. 94:2002;2169-2173.
42. ® and Taxanes. Oncology. 61:(suppl S2):2001;43-49.
43. ®) in breast cancer. Sem Oncol. 28:(1suppl 3):2001;38-44.
44. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 19:2001;2587-2595.
45. Esteva F., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:(7):2002;1800-1808.
46. Burstein H.J., Kuter I., Richardson P.G., et al. Herceptin and vinorelbine for HER2-positive metastatic breast cancer: a phase II study. Proc ASCO. 102a:2000;. Abstract 392.
47. Thedoulou M., Campos S., Welles G., et al. Preliminary cardiac safety and efficacy from a phase I/II trial of TLC D-99 and trastuzumab in patients with locally advanced or metastatic breast cancer. Proc ASCO. 20:2001;40A. abstr 180.
48. Burstein H.J., Harris L.N., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicine- cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 1:(21(1)):2003;46-532003.
49. ®): results of a French compassionate use program. Breast Cancer Research and Treatment. 76:(1):2002;. Abstr 425.
50. Tagliabue E., Agresti R., Carcangiu M.L., et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet. 362:2003;527-533.
51. ®) plus docetaxel vs docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Proc ECCO. 2003;. Abstr 672.
52. Massarweh S., Shou J., DiPietro M., et al. Targeting the epidermal growth factor receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. Breast Cancer Research and Treatment. 76:(1):2002;. Abstr 18.
53. Lipton A., Ali S.M., Leitzel K., et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole vs tamoxifen. J Clin Oncol. 21:(10):2003;1967-1972.
54. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 49:(10):2003;1579-1598. Review.
55. Baselga J., Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. (12 supl 1):2001;S35-S41.
56. Normanno N., Campiglio M., De Luca A., et al. Cooperative inhibitory effect of ZD 1839 (Iressa) in combination with trastuzumab on human breast cancer cell growth. Proc AACR. 2001;. Abst 4156.
57. Albanell J., Baselga J. Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst. 93:(24):2001;1830-1832.
58. ®). J Natl Cancer Inst. 93:(24):2001;1852-1857.
59. Sholl S., Beuzeboc P., Pouillart P. Targeting HER2 in other tumor types. Annals Oncol. 12:(Suppl 1):2001;S81-S87.